An Early Phase 1 interventional study of Psilocybin 25 mg and Functional Magnetic Resonance Imaging (fMRI) in Prolonged Grief Disorder, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by University of Virginia · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Prolonged Grief Disorder with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Prolonged Grief Disorder · United States.
Among the 15 studies in Prolonged Grief Disorder with a site in United States, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1, and was the 11th registered.
40 studies on the registry are indexed under Prolonged Grief Disorder; 14 are open to participants now.
Browse Prolonged Grief Disorder studies →4 of the 15 studies in Prolonged Grief Disorder with a site in United States are open now. Recruiting first, the newest first:
RAND · Sites in United States
Ages 18+
University of Pittsburgh · Sites in United States
Ages 8+
Medical College of Wisconsin · Sites in United States
Ages 40–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Prolonged Grief Disorder studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 73 across 36 interventional studies indexed under Prolonged Grief Disorder.
Median enrollment 42 across the 14 interventional studies, 0 across the 1 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 1 study filed under Prolonged Grief Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies in Prolonged Grief Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05026827Medical College of WisconsinIyengar Yoga for Prolonged Grief Disorder | 2026-12 |
| NCT07318090University of PittsburghF-PGT - Prolonged Grief Treatment for Families Affected by Suicide | 2026-12-31 |
| NCT06724289University of VirginiaPsilocybin for Prolonged Grief Disorder | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Prolonged Grief Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
The study aims to investigate whether a single dose of 25 mg psilocybin can reduce the symptoms of grief and trauma associated with Prolonged Grief Disorder (PGD). It is hypothesized that psilocybin will significantly reduce the symptoms of PGD, and that the treatment will facilitate subjective mystical, spiritual, or insightful experiences, which in turn may contribute to the alleviation of grief and trauma symptoms. Neuroimaging will be used to help researchers better understand the relationship between grief and brain functions, comparing pre- and post-dose scans. Participants will undergo two MRI (magnetic resonance imaging) where they are asked to look at images (this is called a functional MRI or fMRI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
General medical exclusion criteria:
General psychiatric exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg psilocybin administered to each participant
Drug: Psilocybin 25 mg · Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI)
25 mg psilocybin administered to each participant in single arm, open-label trial
There are two "fMRIs" (functional magnetic resonance imaging) that take place 1-14 days before and 1-14 days after psilocybin administration.
Recruitment Rate
Number of participants enrolled divided by number screened over the recruitment period.
Time frame: Through end of enrollment period
Dropout Rate
Proportion of enrolled participants who withdraw or are lost to follow-up prior to completing the 6-month assessment.
Time frame: Baseline to 6-month Follow-up
Change in Prolonged Grief Disorder Symptoms (ICG)
Change in the Inventory of Complicated Grief (ICG) is a 19-item scale assessing prolonged grief symptoms. Scores range from 0 to 76, with higher scores indicating greater symptom severity.
Time frame: Baseline (Visit 0 - Screening) to 6-month Follow-up
Change in PTSD Symptoms (DTS)
Change in Davidson Trauma Scale (DTS) total score; range 0-136; higher scores indicate more severe PTSD symptoms.
Time frame: Baseline (Visit 0 Screening) to 6-month Follow-up
Mystical Experience (MEQ)
Change in Mystical Experiences Questionnaire (MEQ-30) mean score; range 0-5; higher scores indicate greater mystical-type experience.
Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up
Altered States of Consciousness (5-D ASC)
Change in 5-Dimensions of Altered States of Consciousness score; range 0-100%; higher percentages indicate greater altered-state intensity.
Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up
Awe Experience (AWE-S)
Change in Awe Experience Scale mean score; range 1-7; higher scores indicate greater awe.
Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up
Challenging Experiences (CEQ)
Change in Challenging Experiences Questionnaire mean score; range 0-5; higher scores indicate more intense challenging experiences.
Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up
Psychological Flexibility (AAQ-II)
Change in Acceptance and Action Questionnaire-II total score; range 7-49; higher scores indicate greater psychological inflexibility.
Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up
Closeness to Others (IOS)
Change in Inclusion of Others in the Self single-item score; range 1-7; higher scores indicate greater perceived interpersonal closeness.
Time frame: Baseline (Visit 0 - Screening) to 6-month Follow-up
Meaning in Life (MIL)
Change in Meaning in Life Questionnaire Presence and Search subscales; each subscale range 5-35; higher scores indicate greater presence of meaning (Presence) or search for meaning (Search).
Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up
Psychological Insight (PIQ)
Change in Psychological Insight Questionnaire mean score; range 0-5; higher scores indicate greater psychological insight.
Time frame: Baseline (Visit 3 - Treatment Visit) to 6-month Follow-up
Personality Traits (NEO-FFI)
Change in the NEO Five-Factor Inventory (NEO-FFI) is a 60-item measure assessing five personality domains: Neuroticism, Extraversion, Openness, Agreeableness, and Conscientiousness. Each domain score ranges from 0-48, with higher scores indicating greater expression of the corresponding personality trait.
Time frame: Baseline (Visit 2 - Preparation for Treatment) to 6-month Follow-up
Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin